← Back

Perrigo Company PLC

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Price · split & dividend adjusted
News & notes moving PRGO
PRGO▲

Perrigo Reaffirms 2026 Outlook as Q2 Core Adjusted EPS Beats Expectations

Perrigo reported second-quarter 2026 core adjusted earnings per share of $0.46, beating expectations, and reaffirmed its full-year outlook. Interim President and CEO Albert Manzone highlighted market share gains of 50 basis points in both U.S. store brand OTC and European key brands, despite category softness. Core net sales declined 3.1% year-over-year, impacted by lower seasonal demand and retailer destocking, while all-in net sales fell 3.2%, partly offset by a 23% increase in Infant Formula. The company applied the majority of $359 million in proceeds from the Dermacosmetics divestiture to debt reduction, and its operational enhancement program remains on track to deliver $80 million to $100 million in savings by 2027. Perrigo maintained its full-year guidance for net sales, margins, and earnings per share, with results expected to be weighted toward the second half.
PRGO ▲
The Motley Fool·14dRead more ▾
PRGO▲

Biotech Stocks Surge on Earnings and Debuts

Several biotech companies posted sharp gains on Wednesday, led by Attovia Therapeutics' 28% surge on its Nasdaq debut and American Well's 25% jump after narrowing its quarterly loss. Attovia priced its IPO at $17 per share and closed at $21.90, while American Well reported a net loss of $9.6 million, or $0.59 per share, down from $19.5 million, or $1.24 per share, a year earlier, though revenue fell to $52.0 million from $70.9 million. Perrigo swung to a net income of $74.5 million, or $0.53 per share, from a loss of $8.4 million, or $0.06 per share, despite a slight revenue dip to $1.02 billion. UroGen Pharma climbed over 16% after total revenue more than doubled to $72.5 million, driven by its bladder cancer drug ZUSDURI, and its net loss narrowed to $14.4 million from $49.9 million. Geron rose 21% as net product revenue increased to $57.5 million from $49.0 million, fueled by higher RYTELO sales, and it forecast full-year RYTELO revenue of $220 million to $240 million.
AMWL ▲GERN ▲PRGO ▲URGN ▲
RTTNews·21dRead more ▾
PRGO▲2

Perrigo swings to profit in Q2, reaffirms FY26 outlook, shares surge

Perrigo reported a second-quarter net income of $74.5 million, swinging from a loss of $8.4 million a year earlier, and reaffirmed its full-year 2026 outlook, sending shares up 11.21% in pre-market trading. Earnings per share were $0.53 compared to a loss per share of $0.06 last year, while adjusted earnings per share fell to $0.50 from $0.57. Net sales declined to $1.02 billion from $1.06 billion, and operating income dropped to $23.5 million from $45.4 million. The company expects full-year 2026 net sales growth to decline between 5.5% and 1.5%, with adjusted earnings per share in the range of $2.00 to $2.30.
PRGO ▲
RTTNews·21dRead more ▾
PRGO

Perrigo Appoints Salman Amin and Omer Gajial as Independent Directors

Perrigo Company has appointed Salman Amin and Omer Gajial as independent directors to its board, effective June 30, 2026. Salman Amin, age 66, brings over 30 years of global consumer products experience, most recently serving as CEO of pladis Global. Omer Gajial, age 52, has extensive retail, e-commerce, and consumer health experience and currently serves as CEO of GoTo Foods. Board Chair Orlando Ashford stated that both individuals bring deep experience across consumer products, retail, and digital transformation that will be valuable as Perrigo advances its strategic priorities.
PRGO
PR Newswire·57dRead more ▾
© 2026 MarketDXAsset